Premium
Development of Inhalable Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in Microparticulate System for Antituberculosis Drug Delivery
Author(s) -
Miranda Margarida S.,
Rodrigues Márcia T.,
Domingues Rui M. A.,
Costa Rui R.,
Paz Elvira,
RodríguezAbreu Carlos,
Freitas Paulo,
Almeida Bernardo G.,
Carvalho Maria Alice,
Gonçalves Carine,
Ferreira Catarina M.,
Torrado Egídio,
Reis Rui L.,
Pedrosa Jorge,
Gomes Manuela E.
Publication year - 2018
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201800124
Subject(s) - drug delivery , drug , nanotechnology , targeted drug delivery , dry powder inhaler , tuberculosis , iron oxide nanoparticles , drug carrier , nanoparticle , superparamagnetism , materials science , pharmacology , medicine , immunology , pathology , asthma , inhaler , magnetization , physics , quantum mechanics , magnetic field
Tuberculosis (TB) is an infectious disease which affects millions of people worldwide. Inhalable polymeric dry powders are promising alternatives as anti‐TB drug carriers to the alveoli milieu and infected macrophages, with potential to significantly improve the therapeutics efficiency. Here, the development of a magnetically responsive microparticulate system for pulmonary delivery of an anti‐TB drug candidate (P3) is reported. Microparticles (MPs) are developed based on a cast method using calcium carbonate sacrificial templates and incorporate superparamagnetic iron oxide nanoparticles to concentrate MPs in alveoli and enable drug on demand release upon actuation of an external alternate magnetic field (AMF). The MPs are shown to be suitable for P3 delivery to the lower airways and for alveolar macrophage phagocytosis. The developed MPs reveal unique and promising features to be used as an inhalable dry powder allowing the AMF control over dosage and frequency of drug delivery anticipating improved TB treatments.